HER-2 Positive Breast Cancer Clinical Trial
— LongHerOfficial title:
Observational, Cross-sectional Study to Analyze the Characteristics of Disseminated Her2+ Breast Cancer Patients Treated With Trastuzumab That Have Reached Complete Remission, Partial Remission or Stabilization of Disease During More Than 3 Years
Main objective: To analyze the clinical and biological characteristics of patients with
disseminated breast cancer HER2 + treated with trastuzumab that have achieved a complete
remission, partial or stable disease for a period exceeding 3 years.
In addition, there will be a sub-genetic analysis of patients in whom there is availability
a sample of primary tumor preserved in paraffin. This sub-analysis will not interfere with
routine clinical practice, as the tumor samples based on which will be held on genetic
profile, have been preserved in paraffin was extracted from the primary tumor to the
patient.
Status | Completed |
Enrollment | 114 |
Est. completion date | September 2011 |
Est. primary completion date | March 2011 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Women older than 18. 2. Patients with disseminated breast cancer with overexpression of HER-2 (IHC 3 + or FISH +). 3. Patients who have been treated with trastuzumab (Herceptin ®). 4. Complete remission, partial or stable disease for a period exceeding 3 years, except for exclusive cerebral progression. 5. Patients who have given their written informed consent. Exclusion Criteria: 1- Patients with remission achieved with surgery or less than three months of treatment with trastuzumab. |
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
Spain | Hospital oncológico de Galicia | A Coruña | |
Spain | Hospital Príncipe de Asturias | Alcalá de Henares | Madrid |
Spain | Hospital de Alcoy Virgen de los Lirios | Alcoy | Alicante |
Spain | Hospital Punta de Europa | Algeciras | Cádiz |
Spain | Hospital Germans Trias i Pujol | Badalona | Barcelona |
Spain | Hospital Clinic i Provincial | Barcelona | |
Spain | Hospital Sant Pau | Barcelona | |
Spain | Hospital General Yagüe | Burgos | |
Spain | Hospital San Pedro de Alcántara | Cáceres | |
Spain | Hospital de Getafe | Getafe | Madrid |
Spain | Hospital Clínico San Cecilio | Granada | |
Spain | Hospital Virgen de las Nieves | Granada | |
Spain | Hospital de Guadalajara | Guadalajara | |
Spain | Hospital Juan Ramón Jiménez | Huelva | |
Spain | Hospital de Igualada | Igualada | Barcelona |
Spain | Hospital de Jerez | Jerez de la Frontera | Cádiz |
Spain | Hospital Universitario de Canarias | La Laguna | Tenerife |
Spain | Hospital Universitario Severo Ochoa | Leganés | Madrid |
Spain | Fundación Jiménez Díaz | Madrid | |
Spain | Hospital Clínico San Carlos | Madrid | |
Spain | Hospital La Paz | Madrid | |
Spain | Hospital Ramón y Cajal | Madrid | |
Spain | Hsopital Doce de Octubre | Madrid | |
Spain | MD Anderson | Madrid | |
Spain | Hospital Virgen de la Victoria | Málaga | |
Spain | Hospital Central Universitario de Asturias | Oviedo | Asturias |
Spain | Hospital Son Llatzer | Palma de Mallorca | Baleares |
Spain | Hospital Quirón | Pozuelo de Alarcón | Madrid |
Spain | Hospital Serranía de Ronda | Ronda | Málaga |
Spain | Hospital Universitario de Salamanca | Salamanca | |
Spain | Hospital de Donostia | San Sebastián | Guipúzcoa |
Spain | Hospital Universitario Nuestra Señora de la Candelaria | Santa Cruz de Tenerife | Tenerife |
Spain | Hospital Nuestra Señora De Valme | Sevilla | |
Spain | Hospital Virgen del Rocío | Sevilla | |
Spain | Mutua de Terrassa | Terrassa | Barcelona |
Spain | Hospital La Fe | Valencia | |
Spain | Hospital Río Hortega | Valladolid | |
Spain | Hospital Provincial de Zamora | Zamora | |
Spain | Hospital Miguel Servet | Zaragoza |
Lead Sponsor | Collaborator |
---|---|
Asociación para el Progreso de la Oncología en Málaga | Roche Farma, S.A |
Spain,
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01432223 -
Primary Chemotherapy With Anthracycline Followed by Nab-paclitaxel and Trastuzumab
|
Phase 2 | |
Completed |
NCT01305941 -
A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
|
Phase 2 | |
Recruiting |
NCT05871918 -
A Multicenter, Randomized, Open, Phase III Trial of ddEC-THPvs Evaluating the Efficacy and Safety of TCHP Neoadjuvant Therapy for HER2-positive Breast Cancer
|
Phase 3 | |
Terminated |
NCT02598310 -
Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02568839 -
Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT02675231 -
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT02154529 -
Study of the Combination of KD019 and Trastuzumab in Subjects With HER2-Positive Metastatic Breast Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01565200 -
HER2 Imaging Study to Identify HER2 Positive Metastatic Breast Cancer Patient Unlikely to Benefit From T-DM1
|
Phase 2 | |
Completed |
NCT01340430 -
Neoadjuvant 5-fluorouracil, Epirubicin and Cyclophosphamide (FEC) Followed by Weekly Paclitaxel and Trastuzumab in Her2 Positive Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02947685 -
Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer
|
Phase 3 | |
Completed |
NCT02066532 -
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01677455 -
An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer
|
Phase 2 | |
Completed |
NCT01583426 -
Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
|
Phase 3 | |
Withdrawn |
NCT01361945 -
AUY922 With Lapatinib and Letrozole for ER+ HER2+ Advanced Breast Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02326974 -
T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA
|
Phase 2 | |
Not yet recruiting |
NCT04644406 -
PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study
|
||
Terminated |
NCT02131506 -
A Study of Lapatinib in Combination With Caelyx in Patients With Advanced HER2 Positive Pretreated Breast Cancer
|
Phase 1 | |
Completed |
NCT00788931 -
A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer
|
Phase 1 | |
Completed |
NCT02488564 -
A Study of Liposomal Doxorubicin + Docetaxel + Trastuzumab + Metformin in Operable and Locally Advanced HER2 Positive Breast Cancer
|
Phase 2 | |
Completed |
NCT02492711 -
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
|
Phase 3 |